Courtiol P, Maussion C, Moarii M, Pronier E, Pilcer S, Sefta M, Manceron P, Toldo S, Zaslavskiy M, Le Stang N et al..
2019.
Deep learning-based classification of mesothelioma improves prediction of patient outcome.. Nat Med. 25(10):1519-1525.
Rai R, Yadav SS, Pan H, Khan I, O'Connor J, Alshalalfa M, Davicioni E, Taioli E, Elemento O, Tewari AK et al..
2019.
Epigenetic analysis identifies factors driving racial disparity in prostate cancer.. Cancer Rep (Hoboken). 2(2):e1153.
Chen HJoyce, Poran A, Unni AM, Huang SXuelian, Elemento O, Snoeck H-W, Varmus H.
2019.
Generation of pulmonary neuroendocrine cells and SCLC-like tumors from human embryonic stem cells.. J Exp Med. 216(3):674-687.
Gilvary C, Madhukar N, Elkhader J, Elemento O.
2019.
The Missing Pieces of Artificial Intelligence in Medicine.. Trends Pharmacol Sci. 40(8):555-564.
Berger A, Brady NJ, Bareja R, Robinson B, Conteduca V, Augello MA, Puca L, Ahmed A, Dardenne E, Lu X et al..
2019.
N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer.. J Clin Invest. 129(9):3924-3940.
Springer NL, Iyengar NM, Bareja R, Verma A, Jochelson MS, Giri DD, Zhou XK, Elemento O, Dannenberg AJ, Fischbach C.
2019.
Obesity-Associated Extracellular Matrix Remodeling Promotes a Macrophage Phenotype Similar to Tumor-Associated Macrophages.. Am J Pathol. 189(10):2019-2035.
Karass M, Bareja R, Shelkey E, Vlachostergios PJ, Robinson BD, Khani F, Mosquera JMiguel, Scherr DS, Sboner A, Tagawa ST et al..
2019.
Oncogenic Addiction to ERBB2 Signaling Predicts Response to Trastuzumab in Urothelial Cancer.. J Natl Compr Canc Netw. 17(3):194-200.
Sivakumar R, Chan M, Shin JStella, Nishida-Aoki N, Kenerson HL, Elemento O, Beltran H, Yeung R, Gujral TS.
2019.
Organotypic tumor slice cultures provide a versatile platform for immuno-oncology and drug discovery.. Oncoimmunology. 8(12):e1670019.
Lue JK, Prabhu SA, Liu Y, Gonzalez Y, Verma A, Mundi PS, Abshiru N, Camarillo JM, Mehta S, Chen EI et al..
2019.
Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas.. Clin Cancer Res. 25(17):5271-5283.